The Global In-Situ Hybridization Market is Expected to Grow at a CAGR of 11.7% from 2014 to 2019

FORT WORTH, Texas, December 19, 2014 /PRNewswire/ --

The in-situ hybridization market was valued at $927.5 million in 2013 and is expected to grow at a CAGR of 11.7% from 2014 to 2019. The report segments in-situ hybridization market on the basis of product, application, technology, and geography. With a range of applications including diagnosis of cancer, cell biology, immunology and neuroscience, fluorescent imaging techniques are widely preferred by scientists in medical as well as academic sectors. As life science suppliers continue improving products and services in the fluorescent imaging market, fluorescent imaging kits and reagents becomes a key growth area in the life sciences industry.

Browse through the TOC of Global in-situ hybridization market for an in-depth analysis of the industry trends and segments, with help of various tables and figures.

http://www.micromarketmonitor.com/market-report/in-situ-hybridization-reports-5740146856.html

Early buyers will receive 10% customization on this report.  

The global in-situ hybridization market is further segmented with respect to geographical regions into North America, Europe, Asia-Pacific, and Rest of the World. In 2013, North America is expected to command the largest share of the in-situ hybridization market. This geographic segment is poised to grow at a CAGR of 11.2% from 2014 to 2019.This growth is attributed to the increasing prevalence of breast cancer and lung cancer cases in this region.

Speak to Analyst @http://www.micromarketmonitor.com/contact/5740146856-speak_to_analyst.html

According to the World Health Organization, breast cancer is the second most common type of cancer in the world, with nearly 1.67 million new cases of breast cancer diagnosed in 2012. This represents about 12% of all new cancer cases in the world (and 25% of all cancers in women). Owing to its high prevalence, breast cancer has always been a major area of focus for companies in the market. Silver ISH (SISH) assay technology, a type of CISH, is one of the emerging technologies in the market. Ventana Medical System introduced the 'INFORM HER2 SISH DNA Probe Assay' to detect HER2 gene in breast cancer patients, exclusively in the U.S. SISH is a fully automated method of prenatal cancer diagnostics that saves time by offering faster and consistent results during clinical trials.

In-situ hybridization is mainly used to detect specific nucleic acids sequences for identification of mRNA species, within sample cells or tissue that are morphologically preserved by hybridization. The ISH technique can be classified into two types, fluorescent in-situ hybridization (FISH) and chromogenic/colometric in-situ hybridization (CISH).  ISH-based diagnostic tests/kits are used to identify specific biomarkers in clinical trial candidates with breast, non-small cell lung, and gastric cancers.

Related Reports: 

The North American Hybridization Market has gained a significant share in the total hybridization market.  The market was pegged at $277 million in 2012 and is estimated to achieve $528 million by 2018, with a growing CAGR of 11.2%. The market can be segmented on the basis of types and various types of applications; the report further segments the market into major geographies, companies, and macro indicators.

http://www.micromarketmonitor.com/market/north-america-in-situ-hybridization-1351239813.html

About MicroMarket Monitor: 

MicroMarket Monitor identifies and attends to various unmet needs of different industrial verticals, which include value chain impact analysis. The company publishes about 12000 Market Research Reports on various Micro Markets across the world. The graphical nature and multidimensional analysis of these reports provide advanced Business Intelligence Tools to the clients in that particular target market.

Contact: 
Mr. Chandrasekhar K. 
5601 Bridge Street 
Suite 300 
Fort Worth, TX 76112 
Tel: +1-888-502-0539 
Email: [email protected]

SOURCE MicroMarket Monitor